Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis

Clinical and Experimental Allergy

Volumn 37, Issue 4, 2007, Pages 488-497

  Brimnes, J ^a   Kildsgaard, J ^a   Jacobi, H ^a   Lund, K ^a  

^a ALK ABELLÓ   (Denmark)

Author keywords

Mouse model; Rhinitis; Sublingual immunotherapy

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; PHLEUM PRATENSE EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EOSINOPHIL; EOSINOPHILIA; FEMALE; HELPER CELL; IMMUNOTHERAPY; LYMPH NODE; MOUSE; NONHUMAN; NOSE MUCUS; PHLEUM PRATENSE; PRIORITY JOURNAL; SENSITIZATION; SNEEZING; T LYMPHOCYTE;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; POLLEN; RHINITIS; TH2 CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34047195341     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02624.x     Document Type: Article

References (37)

1. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344:30-7.
2. Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy 2004; 34:520-6.
3. Durham S. ABC of allergies. Summer hay fever. BMJ 1998; 316:843-5.
4. Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J Clin Invest 2004; 114:1389-97.
5. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. AWHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
6. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-12.
7. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185-90.
8. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61:181-4.
9. Bousquet J, Scheinmann P, Guinnepain MT et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999; 54:249-60.
10. Lima MT, Wilson D, Pitkin L et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507-14.
11. La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104:425-32.
12. Marcucci F, Sensi L, Frati F et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy 2003; 58:657-62.
13. Marcucci F, Sensi L, Frati F et al. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 2001; 56:1091-5.
14. Fanta C, Bohle B, Hirt W et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999; 120:218-24.
15. Ippoliti F, De Santis W, Volterrani A et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216-21.
16. Reich M, Zwacka G, Markert UR. Nonspecific plasma proteins during sublingual immunotherapy. Chem Immunol Allergy 2003; 82:99-108.
17. Hellings PW, Ceuppens JL. Mouse models of global airway allergy: what have we learned and what should we do next? Allergy 2004; 59:914-9.
18. Herz U, Renz H, Wiedermann U. Animal models of type I allergy using recombinant allergens. Methods 2004; 32:271-80.
19. Wang J, Palmer K, Lotvall J et al. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998; 102:1132-41.
20. Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282:2258-61.
21. Saito H, Howie K, Wattie J et al. Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology 2001; 104: 226-34.
22. Strath M, Warren DJ, Sanderson CJ. Detection of eosinophils using an eosinophil peroxidase assay. Its use as an assay for eosinophil differentiation factors. J Immunol Methods 1985; 83:209-15.
23. Woodhead JS, Weeks I. Magic Lite design and development. J Biolumin Chemilumin 1989; 4:611-4.
24. McCusker CT. Use of mouse models of allergic rhinitis to study the upper and lower airway link. Curr Opin Allergy Clin Immunol 2004; 4:11-6.
25. Burney P, Malmberg E, Chinn S, Jarvis D, Luczynska C, Lai E. The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. J Allergy Clin Immunol 1997; 99:314-22.
26. Tomaki M, Zhao LL, Lundahl J et al. Eosinophilopoiesis in a murine model of allergic airway eosinophilia: involvement of bone marrow IL-5 and IL-5 receptor alpha. J Immunol 2000; 165:4040-50.
27. McCusker C, Chicoine M, Hamid Q, Mazer B. Site-specific sensitization in a murine model of allergic rhinitis: role of the upper airway in lower airways disease. J Allergy Clin Immunol 2002; 110:891-8.
28. Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol 2001; 1:7-13.
29. Kanaizumi E, Shirasaki H, Sato J, Watanabe K, Himi T. Establishment of animal model of antigen-specific T lymphocyte recruitment into nasal mucosa. Scand J Immunol 2002; 56:376-82.
30. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999; 17:255-81.
31. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
32. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-9.
33. Winkler B, Baier K, Wagner S et al. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy 2002; 32:30-6.
34. Holt PG, Vines J, Britten D. Sublingual allergen administration. I. Selective suppression of IgE production in rats by high allergen doses. Clin Allergy 1988; 18:229-34.
35. Sato MN, Carvalho AF, Silva AO, MacIel M Jr, Fusaro AE, Duarte AJ. Oral tolerance induced to house dust mite extract in naive and sensitized mice: evaluation of immunoglobulin G anti-immunoglobulin E autoantibodies and IgG-IgE complexes. Immunology 1998; 95:193-9.
36. Wolvers DA, Coenen-de Roo CJ, Mebius RE et al. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp-39. J Immunol 1999; 162:1994-8.
37. Unger WW, Hauet-Broere F, Jansen W, van Berkel LA, Kraal G, Samsom JN Early events in peripheral regulatory T cell induction via the nasal mucosa. J Immunol 2003; 171:4592-603.